Antiplatelet agents for chronic kidney disease
Access status:
Open Access
Type
ArticleAuthor/s
Razavian, MonaDi Micco, Lucia
Palmer, Suetonia C
Craig, Jonathan C
Perkovic, Vlado
Zoungas, Sophia
Webster, Angela C
Jardine, Meg J
Strippoli, Giovanni FM
Abstract
To evaluate the benefits and harms of antiplatelet therapy in patients with any form of kidney disease, including patients with CKD not receiving renal replacement therapy (RRT), patients receiving any form of dialysis, and kidney transplant recipients.To evaluate the benefits and harms of antiplatelet therapy in patients with any form of kidney disease, including patients with CKD not receiving renal replacement therapy (RRT), patients receiving any form of dialysis, and kidney transplant recipients.
See less
See less
Date
2013-02-28Licence
OtherFaculty/School
Faculty of Medicine and Health, Sydney Medical SchoolCitation
Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Jardine MJ, Webster AC, Zoungas S, Strippoli GFM. Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD008834.DOI: 10.1002/14651858.CD008834.pub3Share